These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 407597)

  • 1. Neurochemical investigations of the interaction of N,N-dimethyltryptamine with dopaminergic system in rat brain.
    Waldmeier PC; Maître L
    Psychopharmacology (Berl); 1977 Apr; 52(2):137-44. PubMed ID: 407597
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased synthesis of striatal dopamine by N,N-dimethyltryptamine.
    Smith TL
    Life Sci; 1977 Dec; 21(11):1597-601. PubMed ID: 271755
    [No Abstract]   [Full Text] [Related]  

  • 3. N'N-dimethyltryptamine lowers rat brain acetylcholine and dopamine.
    Haubrich DR; Wang PF
    Brain Res; 1977 Aug; 131(1):158-61. PubMed ID: 267501
    [No Abstract]   [Full Text] [Related]  

  • 4. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
    Waldmeier PC; Delini-Stula A; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postnatal development of dopamine deamination in the striatum of the rat.
    Davis AJ; Holzbauer M; Sharman DF
    Br J Pharmacol; 1975 Dec; 55(4):558-60. PubMed ID: 1212563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further studies on the sequence of dopamine metabolism in the rat brain.
    Westerink BH
    Eur J Pharmacol; 1979 Jul; 56(4):313-22. PubMed ID: 477727
    [No Abstract]   [Full Text] [Related]  

  • 7. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids.
    Thiblin I; Finn A; Ross SB; Stenfors C
    Br J Pharmacol; 1999 Mar; 126(6):1301-6. PubMed ID: 10217522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that 5-methoxy-N, N-dimethyl tryptamine is a specific substrate for MAO-A in the rat: implications for the indoleamine dependent behavioural syndrome.
    Squires RF
    J Neurochem; 1975 Jan; 24(1):47-50. PubMed ID: 1053788
    [No Abstract]   [Full Text] [Related]  

  • 10. On the interaction of 5-hydroxytryptophan and 5-hydroxytryptamine with dopamine metabolism in the rat striatum.
    Awazi N; Guldberg HC
    Naunyn Schmiedebergs Arch Pharmacol; 1978 May; 303(1):63-72. PubMed ID: 307696
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceedings: Lack of significance of MAO-B for in vivo deamination of dopamine.
    Waldmeier PC; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R2. PubMed ID: 1143400
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain.
    Holmes JC; Rutledge CO
    Biochem Pharmacol; 1976 Feb; 25(4):447-51. PubMed ID: 938573
    [No Abstract]   [Full Text] [Related]  

  • 13. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychopharmacology of monoamines and their regulatory enzymes.
    Lipton MA
    Adv Biochem Psychopharmacol; 1974; 12(0):443-54. PubMed ID: 4153941
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum.
    Nissbrandt H; Sundström E; Jonsson G; Hjorth S; Carlsson A
    J Neurochem; 1989 Apr; 52(4):1170-82. PubMed ID: 2564423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in rat brain monoamine turnover following chronic antidepressant administration.
    Sugrue MF
    Life Sci; 1980 Feb; 26(6):423-9. PubMed ID: 6154860
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of drugs on the formation of 3-methoxytyramine, a dopamine metabolite, in the substantia nigra, striatum, nucleus accumbens and tuberculum olfactorium of the rat.
    Westerink BH
    J Pharm Pharmacol; 1979 Feb; 31(2):94-9. PubMed ID: 33260
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.
    Waldmeier PC; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):133-40. PubMed ID: 1012333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of piribedil and one of its metabolites on the concentration of homovanillic acid in the rat brain.
    Jori A; Cecchetti G; Dolfini E; Monti E; Garattini S
    Eur J Pharmacol; 1974 Jul; 27(2):245-8. PubMed ID: 4851685
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: time course and time-dependent interactions with amfonelic acid.
    Steranka LR
    Brain Res; 1982 Feb; 234(1):123-36. PubMed ID: 7059818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.